Wiel C M de Lange
Overview
Explore the profile of Wiel C M de Lange including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
844
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ter Beek L, Bolhuis M, Jager-Wittenaar H, Brijan R, Sturkenboom M, Kerstjens H, et al.
BMJ Open
. 2022 Mar;
11(12):e049777.
PMID: 35344503
Objectives: Malnutrition is associated with a twofold higher risk of dying in patients with tuberculosis (TB) and considered an important potentially reversible risk factor for failure of TB treatment. The...
2.
Vogensen V, Bolhuis M, Sturkenboom M, van der Werf T, de Lange W, Anthony R, et al.
Antimicrob Agents Chemother
. 2021 Nov;
66(2):e0182921.
PMID: 34807758
Moxifloxacin is an attractive drug for the treatment of isoniazid-resistant rifampicin-susceptible tuberculosis (TB) or drug-susceptible TB complicated by isoniazid intolerance. However, co-administration with rifampicin decreases moxifloxacin exposure. It remains unclear...
3.
Done M, Akkerman O, Al-Kailany W, de Lange W, de Jonge G, Kleinnijenhuis J, et al.
Infection
. 2020 Apr;
48(4):641-645.
PMID: 32333368
Background: Paradoxical reaction after the initiation of tuberculosis treatment is defined as increased inflammation following effective antimycobacterial treatment. This is a phenomenon that can severely complicate a patient's recovery, potentially...
4.
Bolhuis M, van der Werf T, Kerstjens H, de Lange W, Alffenaar J, Akkerman O
Eur Respir J
. 2019 Aug;
54(6).
PMID: 31439686
No abstract available.
5.
Wolters B, Akkerman O, Aartsma Y, de Lange W, Scholvinck E, van der Werf T, et al.
Eur Respir J
. 2019 May;
54(3).
PMID: 31109988
No abstract available.
6.
Dekkers B, Bolhuis M, Ter Beek L, de Lange W, van der Werf T, Alffenaar J, et al.
Eur Respir J
. 2019 May;
54(3).
PMID: 31048350
No abstract available.
7.
Bolhuis M, Akkerman O, Sturkenboom M, de Lange W, van der Werf T, Touw D, et al.
Ther Drug Monit
. 2019 Mar;
41(2):253-254.
PMID: 30883521
No abstract available.
8.
van Rijn S, Zuur M, Anthony R, Wilffert B, van Altena R, Akkerman O, et al.
Antimicrob Agents Chemother
. 2018 Nov;
63(2).
PMID: 30455232
Multi- and extensively drug-resistant tuberculosis (M/XDR-TB) has become an increasing threat not only in countries where the TB burden is high but also in affluent regions, due to increased international...
9.
Drijver-Messelink M, Kerstjens H, de Lange W, de Vries J, van der Werf T, Akkerman O
Ned Tijdschr Geneeskd
. 2018 Sep;
162.
PMID: 30182637
Tuberculosis is still considered to be a threat to public health in the Netherlands. The Dutch Public Health Act enables the mandatory isolation of contagious patients who are not willing...
10.
Akkerman O, Grasmeijer F, de Lange W, Kerstjens H, de Vries G, Bolhuis M, et al.
Eur Respir J
. 2018 Feb;
51(3).
PMID: 29419442
No abstract available.